RedHill Biopharma (RDHL) has released an update.
RedHill Biopharma has been selected to present its promising drug, Opaganib, at a U.S. government conference focused on chemical, biological, radiological, and nuclear defense. Opaganib, an investigational drug with antiviral, anticancer, and anti-inflammatory properties, has shown significant potential in treating various conditions, including COVID-19 and Ebola. This presentation opportunity underscores RedHill’s growing collaborations with U.S. agencies and highlights Opaganib’s potential as a versatile medical countermeasure.
For further insights into RDHL stock, check out TipRanks’ Stock Analysis page.
